

vaccinations give very good protection before the second dosage, and 36 percent are dubious, 1 to 2 weeks after the second dose (as recommended by the CDC). The public may have been unclear about the necessity for a second dosage since public health specialists disagreed about the proportional advantages of postponing it. A current investigation on the efficacy of the first dosage has yielded a variety of estimates, some of which are far greater than those based on early research. Furthermore, the introduction of new vaccination options provides consumers with a choice that may help them overcome hesitancy; however, when combined with discussions about delaying second doses of other vaccines, this development may increase public confusion and uncertainty about the two-dose protocol, undermining efforts to ensure that as many people as possible return for their second dose. Finally, receiving only one dose of a two-dose COVID-19 vaccination isn't as effective as receiving the entire series. The second dose is strongly advised due to the propagation of the virus and its varieties, as well as the enormous health danger they provide. The first dosage helps your immune system develop, while the second enhances your infection resistance [16]. If we just have one dosage in our high-risk group, those who will have an influence on the health-care system, and we obtain lesser efficacy there, we'll be in danger. When immunity and clinical protection in a population has fallen below a rate regarded sufficient, booster doses (now one or two doses of COVID-19 vaccine depending on the product) are given. A booster dose's goal is to restore vaccination efficacy.

Factors to be considered

Waning immunity: There are yet to be established immunological correlations of protection or duration of protection. In the short term, studies have found a link between vaccine efficacy/effectiveness against symptomatic disease and mean neutralising antibody titers induced by those vaccines, but it is not clear whether decreasing titers over a period of time since vaccination are indicator of decreasing vaccine effectiveness, especially against VoCs [17]. While studies on vaccine immunogenicity imply that antibodies remain for at least six months, neutralising antibodies has been observed to fade. While there is less protection against SARS-CoV-2 infections, there is still protection against serious diseases.

Vaccine effectiveness: Most studies on duration of protection are observational studies. Although often difficult to interpret due to confounding factors 4, emerging data consistently show a decline in vaccine effectiveness against infection and milder forms of COVID-19 over time. With respect to duration of protection against disease requiring hospitalization, current data show an overall continued high level of effectiveness, although data vary across age-groups, target populations, and products [17]. The vast majority of current infections are observed in unvaccinated populations, and if breakthrough infections occur in

vaccinated persons, they are in most cases not more severe than those seen in unvaccinated persons [6].

Global vaccine supply and global and national equity

Decisions on whether or not to add a second dose to a national immunisation programme should be based on the quality of evidence about the need for these doses, their safety and efficacy, and vaccine availability across the world. Giving booster doses to a huge number of individuals while many have yet to get their initial dose goes against the concept of national and global equality. Prioritizing booster doses above speed and breadth in the initial dose coverage might jeopardise global pandemic mitigation efforts, with major health, social, and economic ramifications for individuals [18].

CONCLUSION

Clinical experiments first revealed the advantages of priming with COVID-19 vaccinations. The immunological responses of persons who received one or two vaccination doses were compared in early investigations of the now licenced COVID-19 vaccines. People exhibited higher levels of antibodies to combat the virus after the second dosage, indicating that taking more than one dose would likely boost vaccination efficacy. Only getting one dosage isn't as effective as getting the complete second dose. The second dosage is strongly suggested due to the virus's propagation and the considerable health danger it poses. In India, primary COVID vaccines such as Bharat Biotech's Covaxin and the Serum Institute of India's Covishield should be given in two doses. Even if you've already had the first dose of the vaccination, you must get the second injection.

The second dosage of Covishield can be administered after a 12 weeks hiatus, but the second dose of Covaxin can be taken after 4-6 weeks following the first dose. Only first dose of COVID vaccination gives partial protection, which shows you are at risk of contracting serious COVID infections. Given the new variants that have emerged, it is even more important that you take your vaccination process seriously and follow all of the health officials' guidelines. This strategy of giving patients numerous doses is referred to as "prime-boosting" by immunologists. Essentially, you stimulate the immune system by teaching it what it's searching for with the first vaccine. The immune system is then assaulted again once it has had time to respond to the priming. When the immunological response learnt the first time is put into practise on the second encounter, it is amplified. There's another reason to obtain your second dosage now: new coronavirus strains that are causing worry. These are coronavirus strains with genetic changes that make them more transmissible, less resistant to vaccination protection, more difficult to detect, or cause more severe sickness. Getting your second injection and being completely vaccinated not only reduces your odds of developing COVID-19, but it also assures little to no symptoms if you do. Aside from that, recent findings have revealed that those who have received all of their vaccines are not more vulnerable to

the Delta and Delta plus variants than those who have had only one dose. The second vaccination injection is the most crucial since it delivers complete viral protection. Furthermore, receiving first and second dose of the COVID vaccination can help us acquire herd immunity, which can help us limit the virus's spread in communities. The importance of the second dosage can be attributed to a variety of factors. For starters, it's critical to safeguard oneself against contracting the virus. However, it's equally critical to avoid transmitting it to others.

A vaccine is for our own protection against coronavirus disease. Vaccination against COVID-19 advised for everyone. It is very crucial to take the second dose of COVID vaccine on scheduled time since it increases our immunity on another level. Despite the fact that patients who done with their first dose of the vaccination shows modest protection against symptomatic COVID-19 infection, the immune response to a single dose of the vaccine is not very much strong. What happens if everyone gets the same dose of vaccine is not known. People vaccinated with only single dose of vaccine are less immune against COVID-19 infection, increasing the chance of SARS-CoV-2, the virus that causes COVID-19, becoming vaccine-resistant. There is also a chance that people who just get one dosage will think that they will not get COVID-19 infection and won't need to be treated again. There is no proof that a single dosage of COVID-19 is effective at preventing infection over the long term.

REFERENCES

1. SteelFisher GK, Blendon RJ, Caporello H. An uncertain public encouraging acceptance of COVID-19 vaccines. *N Engl J Med* 2021; 384:1483-1487.
2. Wood S, Schulman K. Beyond politics—promoting Covid-19 vaccination in the United States. *N Engl J Med* 2021; 384:23.
3. Kramer DB, Opel DJ, Parasidis E, et al. Choices in a crisis—individual preferences among SARS-CoV-2 vaccines. *N Engl J Med* 2021; 384:62.
4. Guidry JP, Laestadius LI, Vraga EK, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. *Am J Infect Control* 2021; 49:137-142.
5. Southwell BG, Kelly BJ, Bann CM, et al. Mental models of infectious diseases and public understanding of COVID-19 prevention. *Health Commun* 2020; 35:1707-1710.
6. Brssow H. COVID-19: vaccination problems. *Environ Microbiol* 2021; 23:2878-2890.
7. He Q, Mao Q, Zhang J, et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. *Front Immunol* 2021; 12.
8. Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis* 2021; 21:26-35.
9. Meo SA, Bukhari IA, Akram J, et al. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. *Eur Rev Med Pharmacol Sci* 2021; 1663-1669.
10. Sagili Anthony DP, Sivakumar K, Venugopal P, et al. Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges. *Clin Drug Investig* 2021; 41:499-509.
11. Amanpour S. The rapid development and early success of COVID-19 vaccines have raised hopes for accelerating the cancer treatment mechanism. *Arch Razi Inst* 2021; 76:1.
12. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant—National Healthcare Safety Network, 2021. *Morbidity and Mortality Weekly Report*. 2021; 70:1163.
13. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. *Lancet Infect Dis* 2021; 21:1529-1538.
14. Prendecki M, Willicombe M. Single-dose SARS-CoV-2 vaccination efficacy in the elderly. *Lancet Infect Dis* 2021; 21:1474-1475.
15. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. *Lancet Infect Dis* 2021; 21:1539-1548.
16. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet* 2021; 397:1725-1735.
17. Liu Q, Qin C, Liu M, et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. *Infect Dis Poverty* 2021; 10:1-5.
18. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* 2021; 397:1819-1829.